ResearcherStony Brook UniversityNo recent work listed

Irene Ischenko

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 8 November 2026

Matched on OpenAlex author ID A5110342000. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper

Papers 2

KRAS drives immune evasion in a genetic model of pancreatic cancer. Co-author DOI 10.1038/s41467-021-21736-w ↗
A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells. Co-author DOI 10.18632/oncotarget.4538 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Michael J. Hayman · 2 shared papers, 2015–2021 · strength 0.22
- Paper KRAS drives immune evasion in a genetic model of pancreatic cancer. DOI 10.1038/s41467-021-21736-w ↗
- Paper A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells. DOI 10.18632/oncotarget.4538 ↗
Stephen D’Amico · 1 shared paper, 2021 · strength 0.14
- Paper KRAS drives immune evasion in a genetic model of pancreatic cancer. DOI 10.1038/s41467-021-21736-w ↗
Nancy C. Reich Marshall · 1 shared paper, 2021 · strength 0.14
- Paper KRAS drives immune evasion in a genetic model of pancreatic cancer. DOI 10.1038/s41467-021-21736-w ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.